<DOC>
	<DOCNO>NCT02232932</DOCNO>
	<brief_summary>A prospective , open-label , randomise , multicentre , comparative study two parallel group compare interventional group liver transplantation precede neoadjuvant radio-chemotherapy control group receive conventional liver bile duct resection . The primary endpoint overall survival 5 year intent-to-treat population . The secondary endpoint recurrence-free survival 3 year evaluate CT-scan tumoral marker ( Carcinoembryonic antigen ( CAE ) cancer antigen ( CA19.9 ) ) intent-to-treat population . The number subject necessary 54 patient ( 27 x 2 ) : population enable demonstration significant difference 5-year survival rate transplant group resect group power 80 % first-species risk 5 % , hypothesis survival rate 70 % transplant group 30 % resect group .</brief_summary>
	<brief_title>Liver Resection Versus Radio-chemotherapy-Transplantation Hilar Cholangiocarcinoma</brief_title>
	<detailed_description>The protocol comprise phase 1 potential eligibility patient ( present resectable Klatskin - Excepted Type 1of Bismuth ) assess , base clinical , biological morphological data . After phase 1 , eligibility patient confirm . In context study , phase 2 include collection blood sample well positon emission tomography ( PET ) -scan upper endoscopic ultrasound ( EUS ) order rule obvious lymph node metastasis . A short exploratory laparoscopy also perform phase 2 eliminate infra-clinic subcapsular liver metastasis peritoneal carcinomatosis . The randomization process take place end phase 2 , patient assign transplantation arm ( OLT ) resection arm ( RSX ) . During phase 3 , patient receive nutritional support , do previously , biliary drainage place endoscopically . In RSX arm ( phase 3A ) , patient undergo radical resection tumor ( refer technical detail ) . Preoperative portal vein embolization may necessary stage depend expect remnant liver volume , assess CT-scan volumetry . In OLT arm ( phase 3A ) , patient receive neoadjuvant radiochemotherapy ( External - 50 gray ) follow liver transplantation ( phase 4B ) . Before fifth week completion radiochemotherapy , stag laparotomy local lymphadenectomy perform patient put national wait list absence extra-hepatic disease , especially peritoneal seed lymph node involvement . A score exception allow liver transplantation 3 month stag laparotomy . During phase 5 patient monitor postoperatively clinical , biological morphological level 3 month . During phase 6 , patient follow clinically , biologically morphologically 5 year order detect recurrence context standard clinical care .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Klatskin Tumor</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients ( male female ) age 18 68 yearold , French Hilar cholangiocarcinoma histologically prove and/or highly suspected hilar stenosis mass syndrome 0.1 cm 3 cm Hilar cholangiocarcinoma type 2 , type 3A , type 3B , type 4 Patients consider resectable ( R0 resection ) liver resection include segment 1 biliary confluence without vascular resection Patient potentially transplantable Patient affiliate French Health Insurance Patient sign inform consent Pregnant breastfeed woman Women childbearing potential without effective contraception method Radiotherapy contraindication Percutaneous biliary drainage Positive dosage ImmunoglobulinsG4 ( IgG4 ) Known dihydropyrimidinedehydrogenase ( DPD ) deficit Personal history cancer last 5 five year ( exclusion basocellular cellular carcinoma ) Personal history fluoropyrimidine hypersensibility Personal history capecitabine hypersensibility Personal history dihydropyrimidinedehydrogenase deficit Polynuclear neutrophil &lt; 1500 / ml Platelet rate &lt; 100 000 / ml Severe leucopenia &lt; 2000 / ml Severe liver failure ( Factor V &lt; 50 % ) Severe renal failure ( Creatin clearance &lt; 30 ml/min ) Treatment Sorivudine analogue Brivudine Non control diabetes mellitus and/or others severe comorbidities ( renal failure , severe instable coronaropathy , severe risk factor stroke , body mass index superior 35 ) Proved histological cirrhosis Sclerosing cholangitis Intra and/or extrahepatic metastasis Hypereosinophilia and/or wirsung dilatation and/or mass pancreas head Hilar mass superior 3 cm Duodenal invasion Patient guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Hilar cholangiocarcinoma</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Radiochemotherapy</keyword>
</DOC>